<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(1)</volume><submitter>Levada OA</submitter><pubmed_abstract>BACKGROUND:IGF-1 is an essential neurotrophin produced peripherally and in the brain. Impairments in the brain IGF-1 concentrations might be responsible for some aspects of major depressive disorder (MDD) pathogenesis, whereas peripheral IGF-1 could have the marker value. We aimed: 1) to compare serum IGF-1 levels in MDD patients and healthy controls (HC); 2) to elucidate possible associations between changes in IGF-1 expression and crucial characteristics of the current depressive episode, MDD course; 3) to evaluate IGF-1 dynamics after 8 weeks` vortioxetine treatment. METHODS:Seventy-eight MDD patients (according to DSM-5) and 47 HC were enrolled. Serum IGF-1, psychopathological (MADRS, CGI) and neuropsychological parameters (PDQ-5, RAVLT, TMT-B, DSST) were analyzed in all subjects at ad</pubmed_abstract><journal>BMC psychiatry</journal><pagination>208</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7206727</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.</pubmed_title><pmcid>PMC7206727</pmcid><pubmed_authors>Pinchuk IY</pubmed_authors><pubmed_authors>Levada OA</pubmed_authors><pubmed_authors>Troyan AS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.</name><description>BACKGROUND:IGF-1 is an essential neurotrophin produced peripherally and in the brain. Impairments in the brain IGF-1 concentrations might be responsible for some aspects of major depressive disorder (MDD) pathogenesis, whereas peripheral IGF-1 could have the marker value. We aimed: 1) to compare serum IGF-1 levels in MDD patients and healthy controls (HC); 2) to elucidate possible associations between changes in IGF-1 expression and crucial characteristics of the current depressive episode, MDD course; 3) to evaluate IGF-1 dynamics after 8 weeks` vortioxetine treatment. METHODS:Seventy-eight MDD patients (according to DSM-5) and 47 HC were enrolled. Serum IGF-1, psychopathological (MADRS, CGI) and neuropsychological parameters (PDQ-5, RAVLT, TMT-B, DSST) were analyzed in all subjects at ad</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 May</publication><modification>2025-04-04T22:56:53.262Z</modification><creation>2020-05-22T20:16:03Z</creation></dates><accession>S-EPMC7206727</accession><cross_references><pubmed>32384884</pubmed><doi>10.1186/s12888-020-02636-7</doi></cross_references></HashMap>